Accelerate Diagnostics: Rises as FDA allows emergency use of COVID-19 tests

Accelerate Diagnostics

10/09/2020 15:33

** Diagnostics co's shares  AXDX.O  up 4.86% to $10.46
    ** Co and partner BioCheck Inc receive U.S. FDA emergency
use authorization (EUA) for individual BioCheck SARS-CoV-2 IgM
Test Kit and the BioCheck SARS-CoV-2 IgG Test Kit  urn:newsml:reuters.com:*:nPn16xGfta
    ** AXDX will market, commercialize and support the
serology-based testing platform
    ** Companies earlier received EUA for a fully automated
MS-Fast instrument and the BioCheck SARS-CoV-2 IgM and IgG Combo
Test
    ** The MS-Fast system and BioCheck SARS-CoV-2 tests are
capable of processing human serum samples in 30 minutes to
detect antibodies that indicate recent or prior COVID-19
infection, says company
    ** AXDX stock down ~40% YTD  

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))